Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication

Yu Kai Su, Wen Chien Huang, Wei Hwa Lee, Oluwaseun Adebayo Bamodu, Muhammad Ary Zucha, Indwiani Astuti, Heri Suwito, Chi Tai Yeh, Chien Min Lin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Current standard chemotherapy for late stage ovarian cancer is found unsuccessful due to relapse after completing the regimens. After completing platinum-based chemotherapy, 70% of patients develop relapse and resistance. Recent evidence proves ovarian cancer stem cells as the source of resistance. Therefore, treatment strategy to target both cancer stem cells and normal stem cells is essential. In this study, we developed a novel chalcone derivative as novel drug candidate for ovarian cancer treatment. We found that methoxyphenyl chalcone was effective to eliminate ovarian cancer cells when given either as monotherapy or in combination with cisplatin. We found that cell viability of ovarian cancer cells was decreased through apoptosis induction. Dephosphorylation of Bcl2-associated agonist of cell death protein was increased after methoxyphenyl chalcone treatment that led to activation of caspases. Interestingly, this drug also worked as a G2/M checkpoint modulator with alternative ways of DNA damage signal-evoking potential that might work to increase response after cisplatin treatment. In addition, methoxyphenyl chalcone was able to suppress autophagic flux and stemness regulator in ovarian spheroids that decreased their survival. Therefore, combination of methoxyphenyl chalcone and cisplatin showed synergistic effects. Taken together, we believe that our novel compound is a promising novel therapeutic agent for effective clinical treatment of ovarian cancer.

Original languageEnglish
JournalTumor Biology
Volume39
Issue number5
DOIs
Publication statusPublished - May 2017

Fingerprint

Chalcone
Neoplastic Stem Cells
Ovarian Neoplasms
Cisplatin
Apoptosis
Neoplasms
Therapeutics
Recurrence
Drug Therapy
Caspases
Platinum
Pharmaceutical Preparations
DNA Damage
Cell Survival
Cell Death
Stem Cells
Survival
Proteins

Keywords

  • Apoptosis
  • Autophagy
  • Chemo resistance
  • Methoxyphenyl chalcone
  • Ovarian cancer stem cells
  • Phytochemical
  • Tumorspheres

ASJC Scopus subject areas

  • Cancer Research

Cite this

Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication. / Su, Yu Kai; Huang, Wen Chien; Lee, Wei Hwa; Bamodu, Oluwaseun Adebayo; Zucha, Muhammad Ary; Astuti, Indwiani; Suwito, Heri; Yeh, Chi Tai; Lin, Chien Min.

In: Tumor Biology, Vol. 39, No. 5, 05.2017.

Research output: Contribution to journalArticle

Su, Yu Kai ; Huang, Wen Chien ; Lee, Wei Hwa ; Bamodu, Oluwaseun Adebayo ; Zucha, Muhammad Ary ; Astuti, Indwiani ; Suwito, Heri ; Yeh, Chi Tai ; Lin, Chien Min. / Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication. In: Tumor Biology. 2017 ; Vol. 39, No. 5.
@article{a03af637431e44a2bf54b03904106c48,
title = "Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication",
abstract = "Current standard chemotherapy for late stage ovarian cancer is found unsuccessful due to relapse after completing the regimens. After completing platinum-based chemotherapy, 70{\%} of patients develop relapse and resistance. Recent evidence proves ovarian cancer stem cells as the source of resistance. Therefore, treatment strategy to target both cancer stem cells and normal stem cells is essential. In this study, we developed a novel chalcone derivative as novel drug candidate for ovarian cancer treatment. We found that methoxyphenyl chalcone was effective to eliminate ovarian cancer cells when given either as monotherapy or in combination with cisplatin. We found that cell viability of ovarian cancer cells was decreased through apoptosis induction. Dephosphorylation of Bcl2-associated agonist of cell death protein was increased after methoxyphenyl chalcone treatment that led to activation of caspases. Interestingly, this drug also worked as a G2/M checkpoint modulator with alternative ways of DNA damage signal-evoking potential that might work to increase response after cisplatin treatment. In addition, methoxyphenyl chalcone was able to suppress autophagic flux and stemness regulator in ovarian spheroids that decreased their survival. Therefore, combination of methoxyphenyl chalcone and cisplatin showed synergistic effects. Taken together, we believe that our novel compound is a promising novel therapeutic agent for effective clinical treatment of ovarian cancer.",
keywords = "Apoptosis, Autophagy, Chemo resistance, Methoxyphenyl chalcone, Ovarian cancer stem cells, Phytochemical, Tumorspheres",
author = "Su, {Yu Kai} and Huang, {Wen Chien} and Lee, {Wei Hwa} and Bamodu, {Oluwaseun Adebayo} and Zucha, {Muhammad Ary} and Indwiani Astuti and Heri Suwito and Yeh, {Chi Tai} and Lin, {Chien Min}",
year = "2017",
month = "5",
doi = "10.1177/1010428317691689",
language = "English",
volume = "39",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication

AU - Su, Yu Kai

AU - Huang, Wen Chien

AU - Lee, Wei Hwa

AU - Bamodu, Oluwaseun Adebayo

AU - Zucha, Muhammad Ary

AU - Astuti, Indwiani

AU - Suwito, Heri

AU - Yeh, Chi Tai

AU - Lin, Chien Min

PY - 2017/5

Y1 - 2017/5

N2 - Current standard chemotherapy for late stage ovarian cancer is found unsuccessful due to relapse after completing the regimens. After completing platinum-based chemotherapy, 70% of patients develop relapse and resistance. Recent evidence proves ovarian cancer stem cells as the source of resistance. Therefore, treatment strategy to target both cancer stem cells and normal stem cells is essential. In this study, we developed a novel chalcone derivative as novel drug candidate for ovarian cancer treatment. We found that methoxyphenyl chalcone was effective to eliminate ovarian cancer cells when given either as monotherapy or in combination with cisplatin. We found that cell viability of ovarian cancer cells was decreased through apoptosis induction. Dephosphorylation of Bcl2-associated agonist of cell death protein was increased after methoxyphenyl chalcone treatment that led to activation of caspases. Interestingly, this drug also worked as a G2/M checkpoint modulator with alternative ways of DNA damage signal-evoking potential that might work to increase response after cisplatin treatment. In addition, methoxyphenyl chalcone was able to suppress autophagic flux and stemness regulator in ovarian spheroids that decreased their survival. Therefore, combination of methoxyphenyl chalcone and cisplatin showed synergistic effects. Taken together, we believe that our novel compound is a promising novel therapeutic agent for effective clinical treatment of ovarian cancer.

AB - Current standard chemotherapy for late stage ovarian cancer is found unsuccessful due to relapse after completing the regimens. After completing platinum-based chemotherapy, 70% of patients develop relapse and resistance. Recent evidence proves ovarian cancer stem cells as the source of resistance. Therefore, treatment strategy to target both cancer stem cells and normal stem cells is essential. In this study, we developed a novel chalcone derivative as novel drug candidate for ovarian cancer treatment. We found that methoxyphenyl chalcone was effective to eliminate ovarian cancer cells when given either as monotherapy or in combination with cisplatin. We found that cell viability of ovarian cancer cells was decreased through apoptosis induction. Dephosphorylation of Bcl2-associated agonist of cell death protein was increased after methoxyphenyl chalcone treatment that led to activation of caspases. Interestingly, this drug also worked as a G2/M checkpoint modulator with alternative ways of DNA damage signal-evoking potential that might work to increase response after cisplatin treatment. In addition, methoxyphenyl chalcone was able to suppress autophagic flux and stemness regulator in ovarian spheroids that decreased their survival. Therefore, combination of methoxyphenyl chalcone and cisplatin showed synergistic effects. Taken together, we believe that our novel compound is a promising novel therapeutic agent for effective clinical treatment of ovarian cancer.

KW - Apoptosis

KW - Autophagy

KW - Chemo resistance

KW - Methoxyphenyl chalcone

KW - Ovarian cancer stem cells

KW - Phytochemical

KW - Tumorspheres

UR - http://www.scopus.com/inward/record.url?scp=85020056177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020056177&partnerID=8YFLogxK

U2 - 10.1177/1010428317691689

DO - 10.1177/1010428317691689

M3 - Article

C2 - 28466786

AN - SCOPUS:85020056177

VL - 39

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 5

ER -